Table 5.

Effects of Aurora kinase inhibitors investigated in NHL

Drug	Clinical trial	Patients included	N	Route	Dose	Main toxicity reported	Responses	Reference
MLN8237	Phase I	Haematological malignancies, (including relapsed NHL)	29	PO	35–90 mg bid day 1, then once daily×14 d every 28 days (MTD 90 mg)	Neutropenia, thrombocytopenia, asthenia.	1/19 DLBCL achieved PR.	Padmanabhan et al, (2010)
	Phase II	Relapsed or refractory aggressive NHL	NR	PO	NR	NR	NR	NCT00807495*
AZD1152	Phase II	Relapsed or refractory DLBCL or transformed NHL	NR	IV	NR	NR	NR	NCT01354392*

NHL, non-Hodgkin’s lymphoma; DLBCL, diffuse large B-cell lymphoma; IV intravenous injection; PO, oral; bid, twice daily; MTD, maximum tolerated dose; NR, not reported.

^*ClinicalTrials.gov Identifier number (cited where no report is available).